Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Zara Izadi, Erica J. Brenner, Satveer K. Mahil, et al.
JAMA Network Open (2021) Vol. 4, Iss. 10, pp. e2129639-e2129639
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 161
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 144
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 7, pp. e490-e506
Open Access | Times Cited: 92
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 90
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Dongze Wu, Yingzhao Jin, Yuhan Xing, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102193-102193
Open Access | Times Cited: 62
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Paulina Núñez, Rodrigo Quera, Andrés Yarur
Drugs (2023) Vol. 83, Iss. 4, pp. 299-314
Open Access | Times Cited: 48
Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management
Zarina Mohd Zawawi, Jeevanathan Kalyanasundram, Rozainanee Mohd Zain, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6142-6142
Open Access | Times Cited: 44
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Jean W. Liew, Milena Gianfrancesco, Carly Harrison, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002187-e002187
Open Access | Times Cited: 47
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Mohd Arish, Wei Qian, Harish Narasimhan, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 45
Management of Psoriasis Patients with Serious Infectious Diseases
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2099-2111
Open Access | Times Cited: 8
Blocking TNF signaling may save lives in COVID-19 infection
Vitaly Ablamunits, Christopher Lepsy
Molecular Biology Reports (2022) Vol. 49, Iss. 3, pp. 2303-2309
Open Access | Times Cited: 31
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
Dalin Li, Alexander M. Xu, Emebet Mengesha, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 7, pp. 1130-1133
Open Access | Times Cited: 30
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Pedro Machado, Martin Schäfer, Satveer K. Mahil, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 5, pp. 698-709
Open Access | Times Cited: 16
SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects
Jiantao Zhang, Kellie Hom, Chen‐Yu Zhang, et al.
Pathogens (2024) Vol. 13, Iss. 1, pp. 75-75
Open Access | Times Cited: 6
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis
Cumali Efe, Craig Lammert, Koray Taşçılar, et al.
Liver International (2021) Vol. 42, Iss. 3, pp. 607-614
Open Access | Times Cited: 36
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases
Lianne Kearsley‐Fleet, Min‐Lee Chang, Saskia Lawson‐Tovey, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 998-1005
Open Access | Times Cited: 26
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Ali Al‐Janabi, Z.Z.N. Yiu
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 1-14
Open Access | Times Cited: 26
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, et al.
Gut (2022) Vol. 71, Iss. 7, pp. 1426-1439
Open Access | Times Cited: 25
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 145-156
Open Access | Times Cited: 24
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus
Sebastian Bruera, Xiudong Lei, Hui Zhao, et al.
Lupus Science & Medicine (2023) Vol. 10, Iss. 1, pp. e000750-e000750
Open Access | Times Cited: 13
Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: A cross-sectional cohort study from China
Yifan Hu, Dawei Huang, Yuxiong Jiang, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24096-e24096
Open Access | Times Cited: 5
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Stefan Schreiber, Shomron Ben‐Horin, Rieke Alten, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2342-2364
Open Access | Times Cited: 22
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic
Alessandra Zaccardelli, Zachary S. Wallace, Jeffrey A. Sparks
Current Opinion in Rheumatology (2023) Vol. 35, Iss. 3, pp. 175-184
Open Access | Times Cited: 11
Predictive Factors for COVID-19 Severity in Patients with Axial Spondyloarthritis: Real-World Data from the Romanian Registry of Rheumatic Diseases
Andreea-Iulia Vlădulescu-Trandafir, Violeta‐Claudia Bojincă, Cristina Raluca Gh. Popescu, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 411-411
Open Access
NOTCH signaling in COVID-19: a central hub controlling genes, proteins, and cells that mediate SARS-CoV-2 entry, the inflammatory response, and lung regeneration
Piyush Baindara, Md Bodruzzaman Sarker, Alexander P Earhart, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top